Your browser is no longer supported. Please, upgrade your browser.
Settings
SPRO Spero Therapeutics, Inc. daily Stock Chart
SPRO [NASD]
Spero Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own21.18% Shs Outstand20.10M Perf Week2.45%
Market Cap192.96M Forward P/E- EPS next Y-3.65 Insider Trans0.00% Shs Float15.20M Perf Month-2.34%
Income-46.50M PEG- EPS next Q-1.05 Inst Own53.30% Short Float2.40% Perf Quarter-4.00%
Sales16.20M P/S11.91 EPS this Y18.80% Inst Trans-2.55% Short Ratio4.52 Perf Half Y-3.23%
Book/sh4.97 P/B1.93 EPS next Y-17.40% ROA-38.10% Target Price24.00 Perf Year-14.29%
Cash/sh4.67 P/C2.05 EPS next 5Y24.00% ROE-43.20% 52W Range8.74 - 14.48 Perf YTD-0.16%
Dividend- P/FCF- EPS past 5Y- ROI-37.10% 52W High-33.70% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low9.84% ATR0.55
Employees41 Current Ratio6.90 Sales Q/Q557.10% Oper. Margin- RSI (14)48.37 Volatility5.44% 5.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-58.60% Profit Margin- Rel Volume0.91 Prev Close9.62
ShortableYes LT Debt/Eq0.00 EarningsMar 12 AMC Payout- Avg Volume80.67K Price9.60
Recom1.90 SMA20-0.45% SMA50-2.98% SMA200-9.99% Volume73,461 Change-0.21%
Nov-05-19Reiterated H.C. Wainwright Buy $28 → $35
Sep-09-19Initiated Janney Buy
Feb-09-18Initiated Cantor Fitzgerald Overweight $27
Nov-27-17Initiated Stifel Buy $26
Nov-27-17Initiated Oppenheimer Outperform $30
Nov-27-17Initiated BofA/Merrill Neutral $16
Feb-11-20 08:00AM  Spero Therapeutics Announces Commencement of Rights Offering GlobeNewswire
Feb-05-20 08:00AM  Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development GlobeNewswire
Jan-31-20 06:54PM  Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-30-20 08:00AM  Spero Therapeutics Announces Proposed Rights Offering GlobeNewswire
Jan-16-20 09:01AM  Introducing Spero Therapeutics (NASDAQ:SPRO), A Stock That Climbed 11% In The Last Year Simply Wall St.
Jan-13-20 08:00AM  Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense GlobeNewswire
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-17-19 04:07PM  Here is What Hedge Funds Think About Spero Therapeutics, Inc. (SPRO) Insider Monkey
Dec-12-19 09:42AM  Iterum Down as Sulopenem Antibiotic Fails in Phase III Study Zacks
Dec-05-19 03:53PM  Spero Posts Preliminary Data on SPR720 for Pulmonary Disease Zacks
Dec-04-19 04:01PM  Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease GlobeNewswire
Nov-29-19 03:45PM  Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-26-19 08:30AM  Spero Therapeutics to Host Key Opinion Leader Symposium in December GlobeNewswire
Nov-04-19 06:35PM  Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review GlobeNewswire
Oct-31-19 05:08PM  Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Oct-23-19 12:47PM  How Many Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Do Institutions Own? Simply Wall St.
Oct-03-19 08:00AM  Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial GlobeNewswire
Sep-30-19 05:00PM  Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-26-19 08:30AM  Spero Therapeutics Announces Presentations at IDWeek 2019 GlobeNewswire
Aug-08-19 08:30PM  Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:10PM  Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update GlobeNewswire
Aug-01-19 10:33AM  Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-16-19 08:00AM  Spero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206 GlobeNewswire
Jul-11-19 08:40AM  Did Changing Sentiment Drive Spero Therapeutics's (NASDAQ:SPRO) Share Price Down By 15%? Simply Wall St. -7.02%
Jun-28-19 05:00PM  Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-20-19 08:00AM  Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis GlobeNewswire +5.68%
Jun-17-19 08:30AM  Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference GlobeNewswire +5.84%
Jun-13-19 08:00AM  Spero Announces $10 Million Registered Direct Offering of Common Stock GlobeNewswire +9.80%
May-31-19 05:00PM  Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-09-19 08:15PM  Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:10PM  Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review GlobeNewswire
May-02-19 06:33PM  Expedia Shares Fall as Home-Rental Business Vrbo Goes Slow Bloomberg
10:32AM  Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for Zacks
May-01-19 08:00AM  Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-29-19 07:55AM  Marriott Is Officially Getting Into the Homesharing Business Skift
Apr-08-19 08:30AM  Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases GlobeNewswire
Apr-01-19 04:00PM  Spero Gets Fast Track Designation for SPR994, Shares Improve Zacks
Mar-29-19 08:00AM  Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis GlobeNewswire +6.13%
Mar-19-19 08:00AM  Spero Announces Appointment of Cynthia Smith to its Board of Directors GlobeNewswire
Mar-15-19 08:18AM  Will Spero Therapeutics Continue to Surge Higher? Zacks
Mar-14-19 04:10PM  Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review Business Wire
Mar-13-19 07:52PM  Airbnb, HomeAway lose legal challenge to Santa Monica rules Associated Press
06:21PM  Airbnb, HomeAway lose legal challenge to Santa Monica rules Associated Press
05:55PM  Airbnb Loses Major Fight Over California City's Rental Law Bloomberg
Mar-01-19 08:30AM  Spero Therapeutics to Present at March Investor Conferences GlobeNewswire
Feb-26-19 08:00AM  Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720 GlobeNewswire +7.12%
Feb-21-19 01:52PM  Are Spero Therapeutics, Inc.s (NASDAQ:SPRO) Interest Costs Too High? Simply Wall St.
Feb-08-19 11:52AM  The travel industry is extremely resilient, says Expedia CEO CNBC Videos
10:00AM  Expedia Analysts Grow More Bullish After Strong Earnings Bloomberg
Feb-07-19 11:28PM  Expedia Group Inc. (EXPE) Q4 2018 Earnings Conference Call Transcript Motley Fool
05:19PM  Expedia Shares Jump After 2019 Earnings Forecast Beats Estimates Bloomberg
Feb-04-19 07:00AM  Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994 GlobeNewswire
Jan-29-19 08:00AM  Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial GlobeNewswire
Jan-08-19 08:15AM  The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase Benzinga
Jan-07-19 04:01PM  Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial GlobeNewswire +13.78%
07:30AM  Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI GlobeNewswire
Dec-20-18 01:08PM  DAFNA Capital Management Return, AUM and Holdings Insider Monkey
Nov-28-18 08:25AM  New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-08-18 08:45PM  Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss Zacks +6.37%
04:10PM  Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview GlobeNewswire
Nov-05-18 08:00AM  Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial GlobeNewswire
Oct-26-18 05:59PM  Expedia acquires Pillow and ApartmentJet to conquer the short-term rental market TechCrunch
11:10AM  Expedia Group (EXPE) Q3 Earnings Beat, Revenues Surge Y/Y Zacks
07:07AM  UPDATE 2-Expedia beats profit estimates on HomeAway, travel bookings growth Reuters
Oct-25-18 09:55PM  Expedia Inc Del (EXPE) Q3 2018 Earnings Conference Call Transcript Motley Fool +6.87%
05:39PM  Expedia Earnings Beat Estimates, Fueled by Home-Rentals Growth Bloomberg
01:12PM  War against the superbugs: Mass. biotechs step up to fight antibiotic resistance American City Business Journals
Oct-22-18 11:38AM  What's in the Cards for Expedia Group (EXPE) in Q3 Earnings? Zacks
Oct-17-18 08:55AM  New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-12-18 08:27AM  The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena Zacks
Oct-11-18 08:00AM  Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206 GlobeNewswire
Sep-28-18 08:10AM  The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results Benzinga
Sep-27-18 04:01PM  Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results GlobeNewswire
Sep-25-18 04:01PM  Spero Therapeutics Announces Presentations at IDWeek 2018 GlobeNewswire
Sep-19-18 08:00AM  Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October GlobeNewswire
Sep-13-18 11:23AM  Who Owns Most Of Spero Therapeutics Inc (NASDAQ:SPRO)? Simply Wall St.
Sep-02-18 07:08AM  How to Set Up a Smart Lock for Your Airbnb or Rental Property Consumer Reports
Aug-30-18 06:21AM  Mass. antibiotics developers say the field is getting slowly better American City Business Journals
Aug-28-18 08:00AM  Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference GlobeNewswire
Aug-22-18 07:30AM  Analysis: Positioning to Benefit within Noble, Spero Therapeutics, AK Steel Holding, Matrix Service, First Internet, and Cray Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-14-18 08:00AM  Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors GlobeNewswire
Aug-09-18 04:10PM  Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview GlobeNewswire
Aug-08-18 01:58PM  Expedia Is Coming After Airbnb, Booking in Home Rental Market Bloomberg
Jul-27-18 11:45AM  Expedia shares rally after big earnings beat CNBC
10:27AM  Expedia (EXPE) Beats Q2 Earnings Estimates, Revenues Up Y/Y Zacks
10:16AM  Expedia CEO: Disciplined marketing spend helped deliver o... CNBC Videos
Jul-26-18 05:09PM  Expedia's Bet on Home Rentals Is Finally Starting to Pay Off Bloomberg
Jul-16-18 06:59AM  Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development GlobeNewswire
Jul-12-18 08:10PM  Spero Therapeutics Announces Pricing of Securities Offering GlobeNewswire
Jul-09-18 04:10PM  Spero Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
07:30AM  Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994 GlobeNewswire
Jun-11-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Jabil, Gladstone Investment, Spero Therapeutics, Jagged Peak Energy, Sabre, and Zions New Research Emphasizes Economic Growth GlobeNewswire +5.48%
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire
Jun-05-18 08:00AM  Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018 GlobeNewswire
Jun-01-18 08:00AM  Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June GlobeNewswire +7.14%
May-23-18 08:00AM  Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform GlobeNewswire -6.20%
May-19-18 04:10PM  Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching Benzinga
May-10-18 04:05PM  Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update GlobeNewswire
May-01-18 09:00AM  Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May GlobeNewswire +8.26%
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory; and collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.